September 2020 – Seal Biosciences receives Notice of Publication for patent application 16/878,973 entiltled “Prognostic and Diagnostic Methods for Colorectal Cancer”

April 2020 – Seal Biosciences successfully executes limited fundraising round

December 2019 – Roose lab at UCSF generates new RasGRP1 antibodies

August 2019 – JCI Insight publication supporting value of RasGRP1 as prognostic marker

September 2017 – Seal Biosciences successfully executes limited fundraising round

October 2016 – Seal Biosciences signs collaboration agreement with Roose lab

August 2016 – Seal Biosciences signs agreement with European CRC clinicians

March 2016 – UCSF files patent with Seal Biosciences as licensing partner

May 2015 – Seal Biosciences purchases exclusive license

April 2015 – Roose lab (UCSF) files provisional patent